Efficacy of rituximab as a single-agent therapy for the treatment of Granulomatous and Lymphocytic Interstitial Lung Disease (GLILD) in patients with Common Variable Immunodeficiency (CVID)

Publication date: Available online 5 November 2018Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Lorenzo Cereser, Riccardo De Carli, Rossano Girometti, Alessandro De Pellegrin, Federico Reccardini, Barbara Frossi, Marco De Carli
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research